Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo ¹H-Magnetic Resonance Spectroscopy and Machine Learning.

ABSTRACT: The isocitrate dehydrogenase (IDH) mutation status is an indispensable prerequisite for diagnosis of glioma (astrocytoma and oligodendroglioma) according to the WHO classification of brain tumors 2021 and is a potential therapeutic target. Usually, immunohistochemistry followed by sequencing of tumor tissue is performed for this purpose. In clinical routine, however, non-invasive determination of IDH mutation status is desirable in cases where tumor biopsy is not possible and for monitoring neuro-oncological therapies. In a previous publication, we presented reliable prediction of IDH mutation status employing proton magnetic resonance spectroscopy (¹H-MRS) on a 3.0 Tesla (T) scanner and machine learning in a prospective cohort of 34 glioma patients.

SUBMITTER: Bumes E 

PROVIDER: S-EPMC9179368 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature